ArticleJournal of thrombosis and thrombolysis2025
Acute myocardial infarction in patients with cancer: outcomes and P2Y12 inhibition.
Article in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer patients are at an elevated risk of bleeding and ischemic events. There are limited comparative real-world data on outcomes of all-comer cancer patients after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) compared with non-cancer patients. There are also limited comparative data to guide P2Y12 inhibitor choice in cancer patients undergoing PCI. We queried the TriNetX research database from 2015 to 2023 to identify adult patients who received PCI for AMI. AMI patients were then stratified into cancer and non-cancer patients. Propensity score matching was used to account for imbalances in baseline characteristics. Cancer patients were further categorized into those who received dual antiplatelet therapy (DAPT) with ticagrelor or clopidogrel in addition to aspirin. Outcomes of interest included all-cause mortality and major bleeding at 30-days and 1-year. Of 139,342 patients who underwent PCI for AMI, 6,766 (4.9%) had a history of cancer. Compared with AMI patients without cancer, cancer patients had higher 1-year all-cause mortality (20.1% vs. 12.7%; HR 1.59; 95% CI, 1.46-1.73) and major bleeding (16.9% vs. 10.2%; HR 1.69; 95% CI 1.54-1.86). Among cancer patients with AMI, those treated with ticagrelor-based DAPT after PCI had similar incidence of bleeding complications compared with those treated with clopidogrel (HR 1.04; 95% CI 0.77-1.40). Cancer is an adverse prognostic marker for AMI outcomes and is independently associated with substantially higher mortality and bleeding risk. Among cancer patients undergoing PCI for AMI, ticagrelor use is associated with similar bleeding events compared with clopidogrel.
Indexed as
Identifiers
40167885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.